MP-04.06 Value of a Combination Assay of Survivin, Calreticulin and Urokinase type- Plasminogen Activator as a Non-Invasive Diagnostic Tool in Non-Muscle Invasive Bladder Cancer

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S51-S52
Author(s):  
W. Sameh ◽  
E. Diab ◽  
F. Dwidar ◽  
A. Ketat ◽  
S. Sharaf
Keyword(s):  
Bladder Cancer ◽  
Plasminogen Activator ◽  
Diagnostic Tool ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Non Invasive ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Muscle Invasive

Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?

2012 ◽  
Vol 30 (6) ◽  
pp. 761-767 ◽  
Author(s):  
Ahmed F. Kotb ◽  
Evan Kovac ◽  
Wassim Kassouf ◽  
Joe Chin ◽  
Yves Fradet ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Outcomes ◽  
Radical Cystectomy ◽  
Invasive Disease ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Non Invasive ◽  
Muscle Invasive

Bladder cancer

2017 ◽  
Author(s):  
Richard P. Meijer ◽  
Alexandre R. Zlotta ◽  
Bas W.G. van Rhijn
Keyword(s):  
Bladder Cancer ◽  
High Specificity ◽  
Invasive Bladder Cancer ◽  
Urinary Cytology ◽  
High Grade ◽  
Muscle Invasive Bladder Cancer ◽  
Non Invasive ◽  
Important Diagnostic Tool ◽  
Moderate Sensitivity ◽  
Muscle Invasive

High-grade non-muscle-invasive bladder cancer (HG-NMIBC) represents the most aggressive spectrum of this non-invasive cancer. This collective term includes all high-grade NMI urothelial carcinoma (UC), such as those without invasion (pTa), those with lamina propria invasion (pT1), and those that are only/have concomitant carcinoma in situ (CIS; pTis). These cancers have a high risk for intravesical recurrence (around 46–78% at five years) and progression (between 6–45% at five years) to muscle-invasive bladder cancer (MIBC). As with all UC, their presentation can be with visible haematuria or irritative lower urinary tract symptoms. The latter are common in patients with CIS. CIS may be detected in isolation (so-called primary CIS) or with a coexisting UC elsewhere (termed concomitant CIS). While urinary cytology has a moderate sensitivity and high specificity (>90%) for the detection of HG-NMIBC, cystoscopy is the most important diagnostic tool.

Low and intermediate risk non-muscle-invasive bladder cancer

2017 ◽  
Author(s):  
Aditya Bagrodia ◽  
Yair Lotan
Keyword(s):  
Bladder Cancer ◽  
Muscularis Propria ◽  
Invasive Bladder Cancer ◽  
Common Disease ◽  
Intermediate Risk ◽  
Muscle Invasive Bladder Cancer ◽  
Non Invasive ◽  
Muscle Invasive ◽  
Muscle Invasion

Bladder cancer is a common disease that affects more males than females. Most bladder tumours are histologically typed as urothelial cell carcinoma, and these are best divided into cancers invading the muscularis propria and non-invasive malignancies confined to the bladder. The latter are the majority of cancers and include low risk, indolent cancers that may recur within the bladder but not progress to invasion or metastases, and a proportion that subsequently progress to muscle invasion. The risk of intravesical recurrence or progression to invasion from a non-invasive bladder cancer can be stratified as low, intermediate, and high using various pathological factors (such as tumour grade, stage, size, multiplicity, and the presence of carcinoma in situ). In this chapter, we will give an overview of bladder cancer and focus upon tumours at low or intermediate risk of developing future progression to invasion.

Comprehensive targeted gene profiling to determine the genomic signature likely to drive progression of high-grade nonmuscle invasive bladder cancer to muscle invasive bladder cancer.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 568-568
Author(s):  
Abedalrhman Alkhateeb ◽  
Govindaraja Atikukke ◽  
Lisa Porter ◽  
Bre-Anne Fifield ◽  
Dora Cavallo-Medved ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Gene Profiling ◽  
Invasive Bladder Cancer ◽  
Low Grade ◽  
Genomic Profiling ◽  
High Grade ◽  
Single Nucleotide Variants ◽  
Muscle Invasive Bladder Cancer ◽  
Non Invasive ◽  
Muscle Invasive

568 Background: Bladder cancer is the fifth most common cancer and eighth leading cause of cancer related-death in North America. It can present as non-muscle invasive bladder cancer (NMIBC) and/or muscle invasive bladder (MIBC). Although genomic profiling studies have established that low-grade NMIBC and MIBC are genetically distinct, high-grade NMIBC can recur and progress to MIBC [ Knowles, M.A. and C.D. Hurst, 2015]. Low grade, non-invasive bladder cancers are characterized by activating mutations in fibroblast growth factor receptor 3 (FGFR3), HRAS or other pathways of receptor kinase activation. High-grade disease, which is often becomes invasive, is characterized by inactivation of TP53 and Rb pathways [Kim, J., et al.]. Finding a subtype of invasive carcinoma with FGFR3 mutation may suggest an alternate pathway by which low grade, non-invasive pathology could transform into invasive disease [Knowles, M.A. and C.D. Hurst, 2015]. Methods: In this study, using a total of 30 bladder cancer (NMIBC and MIBC) patient samples from Windsor Regional Hospital Cancer Program, we performed comprehensive targeted gene sequencing to identify single nucleotide variants, small insertions / deletions, copy number variants and splice variants in over 500 common tumor genes panel. Results: Preliminary data from our study correlates with previously published mutation landscape for NMIBC and MIBC, and includes mutations in EGFR, FGFR3, FGFR4, PIK3CA, CDK6, ALK, JAK, as well as RET. While mutations in AKT1, BRCA1, CCND1, ERBB2, FGFR1, FGFR2, HRAS, and MET appear to be prevalent in NMIBC, mutations in IDH1 and MAP2K2 appear to be more common in MIBC. Three of the samples used in the study are from patients who progressed from high-grade NMIBC to MIBC. Conclusions: Therefore, have the genomic profiling performed at these two stages, which provides a unique ability to identify the potential “genomic triggers” for the transition.

Evaluation of a 29 gene classifier for basal/non basal prediction in muscle-invasive bladder cancer FFPE samples.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 467-467
Author(s):  
Yves Allory ◽  
Nanor Sirab ◽  
Damien Drubay ◽  
David Gentien ◽  
Aurélien De Reyniès ◽  
...  
Keyword(s):  
Gene Expression ◽  
Bladder Cancer ◽  
Diagnostic Tool ◽  
Predictive Accuracy ◽  
External Validation ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Data Set ◽  
Ffpe Samples ◽  
Muscle Invasive

467 Background: Recent and independent muscle-invasive bladder cancer (MIBC) molecular classifications identified the basal / squamous-like (BASQ) tumours as an intrinsic and robust subtype, with a poor outcome and possible chemosensitivity to cisplatin based regimen, making mandatory the development of a diagnostic tool for their identification in routine samples. Our study aimed to evaluate the diagnostic accuracy of a Nanostring classifier for tumor subtype prediction on FPPE specimens. Methods: Two series of MIBC were used (CIT n = 51 & Stransky n = 22) for which BASQ tumours were identified previously using Affymetrix transcriptome data obtained from frozen samples (Rebouissou, Science Trans Med 2014). 29 genes were selected to predict the basal subtype, RNA expression of matched frozen and FFPE samples was studied using Nanostring technology. To define the classifiers for Affymetrix, frozen and FFPE Nanostring expression matrix on CIT samples the centroid of each cluster was calculated using the expression of 29 genes. Internal validation used leave-one-out cross-validation to train and test the prediction accuracy of the new classifier. For external validation, the CIT samples were used as training set and the Stransky samples as validation set. Predictive accuracy expressed as percentage of correctly classified samples is provided. Results: Correlations between Affymetrix, frozen and FFPE Nanostring data set were checked for gene expression and samples. Using CIT samples as train and test set, the predictive accuracy for BASQ tumour identification was for Affymetrix, frozen Nanostring and FFPE Nanostring classifiers, 90.20% [78.59%; 96.74%], 88.24% [76.13%; 95.56%] and 92.16% [81.12%; 97.82%], respectively. Using training on CIT samples and test on Stransky samples, this predictive accuracy was 90.91% [70.84%; 98.88%] both for Affymetrix, frozen Nanostring and FFPE Nanostring classifiers. Conclusions: The 29 gene expression Nanostring codeset was able to identify reliably basal / squamous like tumours on FFPE samples from MIBC in comparison with the gold standard approach based on transcriptomic profile, appearing as a promising diagnostic tool.

scholarly journals Development of a fully automated chemiluminescence immunoassay for urine monomeric laminin-γ2 as a promising diagnostic tool of non-muscle invasive bladder cancer

2017 ◽  
Vol 5 (1) ◽  
Author(s):  
Masatoshi Nakagawa ◽  
Takashi Karashima ◽  
Masayuki Kamada ◽  
Eisaku Yoshida ◽  
Toru Yoshimura ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Diagnostic Tool ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Chemiluminescence Immunoassay ◽  
Muscle Invasive

scholarly journals Urinary expression of let-7c cluster as a non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder cancer

2020 ◽  
Vol 19 ◽  
pp. e1358-e1359
Author(s):  
M.C. Ferriero ◽  
M. Costantini ◽  
M. Spagnuolo ◽  
M. Varmi ◽  
I. Sperduti ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Invasive Bladder Cancer ◽  
High Grade ◽  
Muscle Invasive Bladder Cancer ◽  
Non Invasive ◽  
Risk Of Disease ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document